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 Resumo 
 Introdução: As doenças linfoproliferativas, em particular 
os linfomas não-Hodgkin e Hodgkin, são raras em doen-
tes com doença inflamatória intestinal. O uso de tiopuri-
nas e infecção pelo vírus Epstein-Barr são reconhecidos 
cofactores que podem aumentar a sua incidência. Outros 
factores de risco como a actividade da doença e o trata-
mento biológico são tema de discussão, não existindo da-
dos suficientes na literatura para confirmar uma potencial 
associação. Métodos: Os autores descrevem um caso de 
linfoma Hodgkin num doente previamente medicado 
com azatioprina e em monoterapia de longa duração com 
infliximab. Conclusões: Este caso destaca a importância 
de reconhecer a possível ocorrência e/ou associação das 
doenças linfoproliferativas com a terapêutica com anti-
factor de necrose tumoral-α.
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 Abstract 
 Introduction: Lymphoproliferative disorders, particularly 
non-Hodgkin’s and Hodgkin’s lymphomas, are rare in pa-
tients with inflammatory bowel diseases. The use of thiopu-
rines and infection by Epstein-Barr virus are well-known co-
factors that can raise its prevalence. Other risk factors such 
as disease activity and biological treatment are the subject 
of discussion, without enough data in the literature to con-
firm a potential association.  Methods: We report a case of 
Hodgkin’s lymphoma in a patient who had been treated with 
azathioprine and was on long-term monotherapy with inflix-
imab.  Conclusions: We stress the importance of recognizing 
the possible occurrence of a lymphoproliferative disorder in 
association with anti-tumor necrosis factor-α therapy
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 The search for an early and sustained mucosal healing, 
the current goal in the treatment of inflammatory bowel 
disease (IBD), led to an increased use of immunomodula-
tors. However, this new paradigm is associated with the 
risk of adverse events, including the emergence of lym-
phoproliferative disorders  [1] . Many processes are in-
volved in this problem, including the direct immunosup-
pressive oncogenic effect of the drugs, the decreased im-
munological surveillance of mutant cells, and the impaired 
immune control of chronic infection by oncogenic mi-
croorganisms such as Epstein-Barr virus (EBV)  [2] .
 In this setting, lymphomas are the most common lym-
phoproliferative disorder, especially non-Hodgkin’s lym-
phomas. Their incidence is slightly high in some popula-
tion groups and can be associated with severe prognosis 
 [3] . Hodgkin’s lymphomas (HL) are rare with a few num-
bers described in the literature  [2, 4–6] .
 We present a case of HL in a patient with Crohn’s dis-
ease (CD) under treatment with infliximab (IFX) and 
previously treated with azathioprine.
 Case Report 
 A 40-year-old man with ileocolonic non-stenotic, non-penetrat-
ing CD since 2000 was treated with azathioprine and IFX for steroid 
dependence in 2004. Afterwards, he underwent clinical and endo-
scopic steroid-free remission, although all immunosuppressive ther-
apy was suspended in 2005, after he developed severe pneumonia.
 Due to iron deficiency anemia that was poorly responsive to 
supplementation therapy and radiologic signs of CD activity, IFX 
was restarted 1 year later at 300 mg (5 mg/kg) every 8 weeks, fol-
lowed by normalization of red blood cell count.
 In September of 2012, after 6 years in remission under IFX 
monotherapy, a routine abdominal ultrasound revealed a hypo-
echoic oval lesion with defined contours, 3.5 cm in diameter, lo-
cated at the fork of the celiac trunk, extrinsic to the liver and pan-
creas ( Fig. 1 ), consistent with a lymphadenopathy on computed 
tomography (CT). Once it was diagnosed as a single adenopathy 
with no characteristics suggesting malignancy, a watch-and-wait 
strategy was adopted.
 The patient remained asymptomatic, and 1 year later, a follow-
up CT showed an oval lesion between the liver and the pancreatic 
head, with 40 × 75 mm, as well as splenomegaly, portal vein en-
largement, and multiple enlarged retroperitoneal lymph nodes. 
There were no radiological signs of active IBD ( Fig. 2 ).
 Complete blood count, C-reactive protein, protein electropho-
resis, and immunoglobulin levels were normal. Viral serological 
tests, including EBV (VCA IgM, VCA IgG, and EBNA), were neg-
ative. Clinical and endoscopic remission was confirmed and values 
of calprotectin were negative. IFX was suspended.
 Endoscopic ultrasound revealed a heterogeneous hypoechoic 
mass, with well-defined limits, adjacent to the pancreatic isthmus 
and portal confluence. Fine needle aspiration was performed 
( Fig. 3 ) and the cytological study showed lymphoid CD20+ popu-
lation, some macrophages, giant cells, and granulomas.
 As these findings were suggestive, but nondiagnostic, of low-
grade B-cell lymphoproliferative disorder, a new endoscopic ultra-
sound with fine needle aspiration was carried out. Histology re-
vealed a small number of nonnecrotizing granulomas and some 
large cells, with obvious nucleolus, of Hodgkin’s type, and intense 
staining for CD30 and CD15 in slight markup background of cells 
CD20+ and CD3+ ( Fig. 4 ), all in favor of the diagnosis of HL. Flow 
cytometry did not show monoclonality. To confirm HL, a laparo-
scopic biopsy was performed, ultimately establishing the diagnosis 
 Fig. 1. Abdominal ultrasound showing hy-
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of classic HL, lymphocyte-rich type, with positive immunohisto-
chemistry for EBV ( Fig. 5 ).
 The immunological panel for EBV was repeated 3 months after 
the first one, where VCA IgG and EBNA IgG were positive; serum 
C-reactive protein for EBV was also positive, with a viral load of 
1,990 copies. In the absence of new symptomatology, this apparent 
incongruence could be explained by a false negative initial test 
(e.g., laboratorial error) or eventually the prozone effect, which is 
rare in the case of EBV.
 Stanford V protocol (cyclophosphamide, doxorubicin, vinblas-
tine, vincristine, bleomycin, etoposide, and prednisone, during 12 






 Fig. 2. Computed tomography image ( a ) 
and 3D reconstruction ( b ) revealing an ex-
pansive lesion between the liver and pan-
creatic head, splenomegaly, and abdominal 
lymphadenopathies. 
 Fig. 3. Endoscopic ultrasound image of the 
hypoechoic mass ( a ) and its fine needle as-
piration ( b ). 
 Fig. 4. Cytologic study of the second fine 
needle aspiration performed showing 
Hodgkin cells in a background of CD20+ 
and CD3+ cells. Magnification ×100 ( a ) 
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complete regression of abdominal lesions was confirmed by CT 
( Fig. 6 ). Presently, the patient remains with CD in remission and 
without signs of lymphoproliferative disorder.
 At this point, with the patient being in remission, it was de-
cided not to perform any treatment and maintain clinical and an-
alytic (including calprotectin) monitoring. In case of recurrence, 
the treatment will be chosen based on the gravity and extension of 
the disease, taking into account therapy contraindications, espe-
cially thiopurines, in this setting.
 Discussion 
 Lymphomas including HL are a known rare comor-
bidity that can emerge in IBD patients. Multiple risk fac-
tors are described including male gender, advanced age, 
genetic mutations, use of immunosuppressive therapy, 
and microorganisms such as EBV, human herpes virus 8, 
human T-lymphotropic virus 1, hepatitis C virus, and  He-
licobacter pylori  [3] .
 There is not enough data to state that its incidence is 
raised in IBD. A recent population-based study including 
2,325 IBD patients showed only an association between 
lymphomas and CD (SIR 3.01, 95% CI, 1.21–6.19), espe-
cially with non-Hodgkin’s lymphoma, regardless of the 
use of thiopurines  [7] . On the other hand, Chiorean et al. 
 [8] in a population of 3,585 IBD patients (CD in 2,277 and 
ulcerative colitis in 1,308), with a total of 30,121 patient/
years follow-up, did not find a significantly increased risk. 
A meta-analysis conducted by Pedersen et al.  [9] revealed 
a tendency for a higher risk of lymphoma in patients with 
CD (SIR 1.42, 95% CI, 0.95–2.12).
 The latest ECCO guidelines on this subject try to 
bring a consensus, stating that patients with IBD have a 
risk of developing hematological malignancies and CD 
patients are more likely to be at risk of lymphoma, in 
particular non-Hodgkin’s lymphoma  [10] . However, it 
is difficult to distinguish the role of inflammation and 
immunomodulators in IBD-associated hematological 
diseases  [1] .
 In fact, inflammation itself plays a role in lymphoma-
genesis in other inflammatory and autoimmune settings. 
Local sites of inflammation may be particularly at risk of 
lymphoproliferation, due to chronic B-cell stimulation 
 [11] . In the French nationwide CESAME study cohort, 
IBD-associated lymphoproliferative disorders involving 
the gastrointestinal tract represent 26% of cases and the 
duration of the disease appears as an independent risk 
factor for lymphoma  [12] . 
 The association between immunosuppressive therapy 
and lymphomas is amply described in the literature. 
a b c
 Fig. 5. Laparoscopic biopsy confirming classic lymphocyte-rich type Hogdkin’s lymphoma ( a ), CD30+ ( b ), with positive immunohis-
tochemistry for Epstein-Barr virus ( c ). Magnification ×400. 
 Fig. 6. Abdominal-pelvic computed tomography after 6 months of 
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Thiopurines, the most frequent immunosuppressants 
used in IBD, can lead to diminished activity of DNA re-
pair mechanism which favors a higher number of muta-
tions. Furthermore, the clonal expansion is unregulated, 
leading to the emergence of lymphoproliferative disor-
ders  [2] . In CESAME, one of the biggest studies until to-
day, the risk of lymphomas, including HL, was 5 times 
higher in patients under thiopurines compared to those 
who were never treated with these drugs  [12] . This excess 
risk is present since the initiation of immunosuppressive 
therapy and remains until its cessation  [11] . The authors 
found no difference between the group that stopped thio-
purines and those who had never been treated with them 
 [12] .
 Lymphomas have also been reported in patients treat-
ed with anti-tumor necrosis factor-α (TNF-α) drugs, 
which could act by decreasing apoptosis and allowing 
proliferation of neoplastic cells  [2] , but in most studies, 
anti-TNF-α appears to have no correlation with lympho-
mas  [10] . In a register-based cohort study conducted by 
Nyboe Andersen et al.  [13] , 56,146 patients were includ-
ed and 8 cases of lymphomas, with 2 HL, were diag-
nosed. There was a risk of 0.90 (95% CI, 0.42–1.91) for 
those who were under anti-TNF-α after adjusting the 
variable to the azathioprine use  [13] . Then, caution must 
be taken, when associating lymphomas with anti-TNF-α 
therapy. In reported series, most of the patients were in 
combined treatment with thiopurines, which are a prov-
en risk factor  [3] . On the other hand, there are case re-
ports in the literature showing partial or complete re-
gression of HL after suspension of anti-TNF-α therapy, 
either for IFX or adalimumab, suggesting a role for these 
drugs  [4, 5] .
 As for the concomitant therapy of anti-TNF-α and 
thiopurines, the absolute risk of lymphoma is not in-
creased compared to the use of thiopurines alone, except 
for the case of hepatosplenic T-cell lymphoma, where 
more than 50% of patients had combined treatment  [3] . 
However, these results must also be analyzed with caution 
because in most series, the number of patients is too low 
to detect significant differences  [10] .
 EBV infection is a well-established risk for IBD-asso-
ciated lymphoproliferative disorders. This virus from the 
herpes family is associated with the development of HL, 
especially in mixed cellularity subtype and in male pa-
tients  [14] . It is responsible for 30–40% of HL in immu-
nocompetent and 80% in immunocompromised patients. 
The association is clear when significantly higher levels of 
immunoglobulin G antibody anti-EBV (VCA, EA, and 
EBNA) are found in patients with HL compared to dis-
ease-free controls. Also the relation between EBNA 1 
(needed for persistence of latent viral infection) and 
EBNA 2 (responsible for transformation of EBV-infected 
lymphocytes) is altered in these patients, with an EBNA 
1:EBNA 2 ratio below 1  [15] . EBV can provide an anti-
apoptotic function, immortalizing the infected B cells 
 [14] . Additionally, thiopurines destroy the natural killer 
and cytotoxic T cells responsible for the restriction of 
EBV proliferation; this lack in immunological surveil-
lance allows the emergence of EBV oncogenic effect  [12] 
increasing the risk of lymphoma.
 Our patient had 4 risk factors for lymphoproliferative 
disorders: male gender, CD and its duration, and EBV 
infection. Treatment with azathioprine was stopped 7 
years before the presentation of HL, so an association 
with this drug was unlikely. IFX may have contributed to 
the development and accelerated growth of HL, but its 
use for 12 months after the radiological detection of HL 
did not result in a worse outcome.
 Currently, there is no algorithm for the diagnosis of 
lymphoproliferative disorders in patients with IBD treat-
ed with immunosuppressors and anti-TNF-α. The sero-
logical markers for EBV must be performed before choos-
ing the therapeutic regime. Combination therapy must be 
avoided in young male patients to prevent the emergence 
of hepatosplenic lymphoma. In EBV-seronegative pa-
tients, thiopurines must be avoided and anti-TNF-α 
monotherapy should be preferred, thus lowering the risk 
of post-mononucleosis lymphomas  [10] . Monitoring 
EBV viral load is recommended in posttransplant set-
tings, but this approach has not been validated for pa-
tients with IBD, as a transitory increase can happen dur-
ing flares  [3] . In patients with headache, fever, enlarged 
lymph nodes, hepatomegaly, or splenomegaly, the pos-
sibility of a lymphoproliferative disorder should be con-
sidered  [10] . In these patients, a diagnostic workup should 
be done and immunosuppressive therapy should be sus-
pended.
 In summary, HL can emerge in IBD patients on im-
munosuppressive therapy and physicians must be aware 
of this possibility. EBV plays a major role in its develop-
ment, and routine EBV serological tests should be done 
to plan the better approach to the individual patient. 
Further studies are necessary to identify risk markers in 
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